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Emerging Multidrug Resistance of MethicillinResistant Staphylococcus aureus in Hand Infections
Rick Tosti, MD, Brian T. Samuelsen, MD, Samantha Bender, BS, John R. Fowler, MD, John Gaughan, PhD,
Alyssa A. Schaffer, MD, and Asif M. Ilyas, MD
Investigation performed at the Department of Orthopaedic Surgery and Sports Medicine, Temple University School of Medicine,
Philadelphia, Pennsylvania

Background: Methicillin-resistant Staphylococcus aureus has been the most commonly identified pathogen in hand infections at urban centers, but the evolving antibiotic sensitivity profiles of methicillin-resistant Staphylococcus aureus are not
known. The purposes of this study are to determine if multidrug resistance in methicillin-resistant Staphylococcus aureus is
emerging and to provide current recommendations for empiric antibiotic selection for hand infections in endemic regions.
Methods: An eight-year longitudinal, retrospective chart review was performed on all culture-positive hand infections
encountered by an urban hospital from 2005 to 2012. The proportions of all major organisms were calculated for each
year. Methicillin-resistant Staphylococcus aureus infections were additionally analyzed for antibiotic sensitivity.
Results: A total of 683 culture-positive hand infections were identified. Overall, methicillin-resistant Staphylococcus
aureus grew on culture in 49% of cases; the annual incidence peaked at 65% in 2007. Over the study period, methicillinresistant Staphylococcus aureus was universally resistant to penicillin, oxacillin, and ampicillin. Clindamycin resistance
significantly increased, approaching 20% by 2012 (p = 0.02). Levofloxacin resistance linearly increased from 12% to 50%
(p < 0.01). Resistance to trimethoprim-sulfamethoxazole, tetracycline, gentamicin, and moxifloxacin was only sporadically
observed. Resistance to vancomycin, daptomycin, linezolid, and rifampin was not observed.
Conclusions: Significant increases in resistance to clindamycin and levofloxacin were observed in recent years, and
empiric therapy with these drugs may have limited efficacy, especially in urban centers.
Clinical Relevance: Hand infections caused by methicillin-resistant Staphylococcus aureus may be developing increasing resistance to clindamycin and levofloxacin in recent years. This longitudinal study examines the effectiveness of
a variety of antibiotics to methicillin-resistant Staphylococcus aureus.

Peer Review: This article was reviewed by the Editor-in-Chief and one Deputy Editor, and it underwent blinded review by two or more outside experts. It was also reviewed
by an expert in methodology and statistics. The Deputy Editor reviewed each revision of the article, and it underwent a final review by the Editor-in-Chief prior to publication.
Final corrections and clarifications occurred during one or more exchanges between the author(s) and copyeditors.

S

taphylococcus aureus is the most commonly cultured organism in hand infections1-6. Traditional management of
acute hand abscesses has been incision and drainage
followed by a regimen of beta-lactam antibiotics such as methicillin, nafcillin, or cephalosporins1,2. However, shortly following
the introduction of methicillin in the 1960s, emerging strains
of methicillin-resistant Staphylococcus aureus (MRSA) were
reported as first occurring in the nosocomial setting and more
recently in the community setting3-10. As MRSA has been more

closely monitored, studies have noted associations with increased treatment failures, inpatient lengths of stay, and healthcare costs4,7,8,11,12. However, a few recent reports have suggested
that treatment failures, costs, and lengths of stay may be equivalent
to non-MRSA infections if an appropriate empiric antibiotic is
selected4,6.
As a result of multiple reports showing a greater prevalence of MRSA in urban settings, the Centers for Disease
Control and Prevention have recommended against selecting a
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given empiric antibiotic if the local resistance is greater than
10% to 15%, and many institutions have now subsequently
excluded beta-lactams from empiric treatment4,13,14. However,
the efficacy of contemporary empiric drug selections is not
known, and the possibility of growing multidrug resistance
exists, as alternative antibiotics are becoming more commonly
selected to cover MRSA. The purposes of this study are to
determine if multidrug resistance in MRSA is emerging and to
provide current evidence that clinicians can reference for empiric inpatient or outpatient treatment of hand infections.
Materials and Methods

A

retrospective study was performed at an urban academic medical center
over an eight-year period from January 1, 2005, through December 31,
2012. After approval was obtained from the institutional review board, all hand
infection cases encountered by the emergency room, outpatient office, or inpatient wards were reviewed. We identified subjects by searching International
Classification of Diseases, Ninth Revision, codes relevant to hand infections,
including codes 681.00, 681.01, 681.02, 682.4, 727.05, 727.9, 883.00, 883.1,
882.01, and 882.00 (cellulitis, abscess, tenosynovitis, and open wounds of the
fingers and hands) but only analyzed those subjects between the ages of eighteen
and eighty-nine years with a culture-positive hand abscess. Demographic and
laboratory data were collected from medical records. Patients with multiple
culture results in the same admission were also identified so that the same
organism was not counted twice. Infections were considered nosocomial if records indicated a history of a surgical procedure, dialysis treatments, catheterizations, hospitalization, or nursing home stays within a year prior to admission.
We calculated the annual frequencies of culture-positive infections for the
three most common isolates (MRSA, methicillin-sensitive Staphylococcus aureus
[MSSA], and Streptococcus pyogenes) and polymicrobial infections. A polymicrobial infection was defined as an infection in which more than one organism
was identified; these were not considered mutually exclusive with the frequencies
of other organisms. MRSA infections were then further analyzed for their antibiotic sensitivity profiles. Isolates were assessed for yearly resistance rates to
ampicillin, oxacillin, penicillin, clindamycin, erythromycin, levofloxacin, moxifloxacin, trimethoprim-sulfamethoxazole, tetracycline, gentamicin, rifampin,
daptomycin, vancomycin, and linezolid. We also performed a post hoc calculation for MSSA resistance to clindamycin and levofloxacin.

Statistical Analysis
Continuous variables were assessed with a linear regression model. Percentages
of categorical variables and drug resistances were assessed for a significant
increasing or decreasing trend with the Cochrane-Armitage trend test. Significance was defined as p < 0.05.

TABLE I Organisms Grown on Culture from Specimens from
Acute Hand Infections, 2005 to 2012
Most common organisms
MRSA (49%)
MSSA (21%)
Polymicrobial (20%)
Streptococcus pyogenes (8%)
Least common organisms
Acinetobacter baumannii
Acinetobacter calcoaceticus
Aspergillus species
Bacillus species
Candida albicans
Candida parapsilosis
Citrobacter freundii
Diptheroid species
Eikenella corrodens
Enterobacter cloacae
Enterococcus faecalis
Escherichia coli
Haemophilus parainfluenzae
Klebsiella pneumoniae
Lactobacillus species
Leclercia adecarboxylata
Mycobacterium avium complex
Pasteurella multocida
Porphyromonas gingivalis
Proteus mirabilis
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus (coagulase-negative)
Staphylococcus epidermidis
Streptococcus (alpha-hemolytic)
Streptococcus anginosus
Streptococcus constellatus
Streptococcus (Groups B, C, F, and G)
Streptococcus intermedius
Streptococcus mitis
Veillonella species

Source of Funding
No external source of funding was used for this study.

Results
Overall Demographic Characteristics
total of 683 culture-positive hand infections were identified over the ninety-six-month collection period. The
average patient age was 41.4 years, and 56% were male; the
average white blood cell count was 10.8 · 103/mL. The most
common etiologies for cases were trauma (75%) and intravenous drug use (21%); bite wounds were causative in 3% of
cases. The average annual frequency of comorbidities was
consistent over the study period for patients with diabetes
(14.6% [range, 12.6% to 28.6%] of the population) and for
patients who were positive for the human immunodeficiency

A

virus (3.3% [range, 0% to 5.7%] of the population). However,
intravenous drug users represented a larger percentage of
people with culture-positive hand infections over the time span
of the study: 13.8% in 2005 and 37.2% in 2012 (p < 0.01).
Patients with a history of cancer or nursing home residence
were each noted in approximately 2% of all hand infections.
MRSA infections were considered to be community acquired in
76% of cases and nosocomial in 24% of cases.
Organisms Grown on Culture per Annum
Overall, MRSA was the organism most commonly grown on
culture, followed by MSSA and then Group A Streptococcus. A
variety of organisms were found in lesser frequencies (Table I).
MRSA was also the most common pathogen identified during

1537
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
V O L U M E 96-A N U M B E R 18 S E P T E M B E R 17, 2 014
d

d

M U LT I D R U G R E S I S TA N C E

IN

HAND INFECTIONS

d

TABLE II Annual Resistance of MRSA to Selected Antibiotics
Annual Resistance
Antibiotic

2005

2006

2007

2008

2009

2010

2011

2012

P Value*

Ampicillin

100%

100%

100%

100%

100%

100%

100%

100%

1

Oxacillin

100%

100%

100%

100%

100%

100%

100%

100%

1

Penicillin G

100%

100%

100%

100%

100%

100%

100%

100%

Erythromycin

100%

90%

98%

94%

85%

96%

100%

92%

0.59

Levofloxacin

12%

22%

37%

39%

33%

41%

43%

50%

<0.01

6%

9%

4%

6%

19%

13%

20%

0.02
0.97

Clindamycin

7.0%

1

Tetracycline

2%

0%

2%

3%

6%

0%

3%

0%

Moxifloxacin

0%

3%

8%

0%

0%

0%

0%

3%

0.17

Trimethoprim-sulfamethoxazole

0%

0%

0%

0%

4%

5%

3%

0%

0.14

Gentamicin

0%

0%

0%

0%

5%

0%

0%

0%

0.50

Rifampin

0%

0%

0%

0%

0%

0%

0%

0%

1

Vancomycin

0%

0%

0%

0%

0%

0%

0%

0%

1

Linezolid

0%

0%

0%

0%

0%

0%

0%

0%

1

Daptomycin

0%

0%

0%

0%

0%

0%

0%

0%

1

*Significance was set at p < 0.05.

every year of the study, and it grew on culture in the following
proportions: 53% in 2005, 63% in 2006, 65% in 2007, 43% in
2008, 47% in 2009, 45% in 2010, 37% in 2011, and 42%
in 2012 (Fig. 1). The number of MSSA infections fluctuated
inversely, with MRSA reaching a nadir in 2006 and 2007 but
increasing to a peak of 27.5% in 2012. A significant increase
(p < 0.01) was observed in the percentage of polymicrobial
infections, as they comprised 7% in 2005, 16% in 2006, 13% in
2007, 30% in 2008, 31% in 2009, 36% in 2010, 37% in 2011,

and 25% in 2012. Streptococcus pyogenes infections were grown
on culture in 6% to 17% of cases per year.
For intravenous drug users and diabetic patients with
hand infections, MRSA remained the most common organism
each year, reaching a peak incidence in 2007 as well. Intravenous drug users had the highest annual percentages of MRSA
of all subgroups. Diabetic patients with hand infections commonly had polymicrobial infections (33% overall [range, 22%
to 50% per year]), but this percentage did not increase over

Fig. 1

The annual percentages of MRSA, MSSA, polymicrobial organisms, and Streptococcus pyogenes grown on culture from specimens from acute hand
infections.
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time. Intravenous drug abusers and people without comorbidities who had hand infections showed increases in polymicrobial infections over time (p < 0.01). Intravenous drug
users had polymicrobial organisms that grew on culture in 8%
of cases in 2005, and this percentage increased to 35% of cases
in 2010 and declined to 20% of cases in 2012.
Staphylococcus aureus Antibiotic Sensitivity Profiles
per Annum
MRSA resistance to clindamycin significantly increased over
the eight-year period (p = 0.02); the three highest percentages
were found from 2010 to 2012 as resistance approached 20%
(Table II). MSSA resistance to clindamycin did not increase
significantly over the study period but was present in 11% of
culture specimens overall (range, 8% to 12% per year). MRSA
resistance to levofloxacin linearly increased over eight years
from 12% to 50% (p < 0.01). MSSA resistance to levofloxacin
did not significantly increase (p = 0.68) over the study period
but was present in 12% of culture specimens overall (range, 9%
to 17% per year). Over the eight years studied, MRSA was
uniformly resistant to ampicillin, oxacillin, and penicillin G;
erythromycin resistance was also common and ranged from
85% to 100% per year. MRSA was only sporadically resistant to
tetracycline, moxifloxacin, trimethoprim-sulfamethoxazole, and
gentamicin. No resistance was observed for rifampin, vancomycin,
linezolid, or daptomycin.
Discussion
RSA has gained attention in the literature and in popular
media as a growing concern, especially in urban environments, as several reports have estimated a high proportion
in hand abscesses ranging from 34% to 73%4,12-18. Our results
agree with prior studies and indicate that MRSA may be found
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in approximately half of all hand infections in urban communities in recent years. Moreover, increased costs, failures in
treatment, and increased mortality have also been associated
with MRSA in endemic regions4,6-9,11,12; however, multiple
studies from our institution have shown that equivalent lengths
of hospital stay to non-MRSA infections can be achieved if
appropriate empiric antibiotic coverage is selected4,6. As MRSA
continues to predominate in urban communities, we sought to
further characterize its antibiotic sensitivities to optimize the
empiric treatment regimen, to reduce treatment delays, and to
improve cost containment associated with hand infections.
MRSA grown on culture from specimens from hand infections was increasingly resistant to clindamycin and levofloxacin
over the eight-year period, and the sensitivity to other antibiotics
did not appear to change. In recent years, MRSA resistance to
clindamycin has approached 20% at our center. Although not
directly answered by the present study, we suspect that the increased use of clindamycin to treat MRSA may be contributory.
In 2005, we adopted a hand infection algorithm to improve the
coverage of MRSA, which largely excluded beta-lactams from
empiric treatment of hand infections4,8. Therapeutics such as
vancomycin, clindamycin, and trimethoprim-sulfamethoxazole
were used with a much greater frequency, and, in particular,
clindamycin was the most commonly prescribed initial antibiotic
for hand infections, representing 40% to 50% of the empiric
selections from 2005 to 2007.
In addition, levofloxacin resistance linearly increased over
the past eight years in our study. A report by MacDougall et al.
noted a significant association between emerging MRSA infections and quinolone prescriptions in a cross-sectional study of
seventeen regional U.S. hospitals; the authors suggested that
quinolones may be driving a selection process for MRSA, but
their conclusions were limited in that the MRSA resistance to

Fig. 2

Multidrug resistance in MRSA by year. The region shaded in pink represents an unacceptable resistance level for use in empiric coverage as defined by the
Centers for Disease Control and Prevention. Antibiotics found to have 100% resistance or sensitivity are not displayed. TMP-SMX = trimethoprimsulfamethoxazole.
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quinolones was not known19. Although levofloxacin is not
commonly prescribed for hand infections, some reputable sources
suggest ‘‘fluoroquinolones’’ as an alternative to penicillin-based
drugs in the presence of an allergy20. Our results suggest that
levofloxacin would not be a wise choice in this class, but moxifloxacin appeared to be an effective quinolone with only sporadic
cases of resistance observed in this series.
Despite the narrowing of antibiotic choices, MRSA infections still remain consistently sensitive to a number of
therapeutics. Tetracycline, gentamicin, moxifloxacin, and
trimethoprim-sulfamethoxazole were resistant in only a few
cases in our study, and no resistance was observed for vancomycin, daptomycin, linezolid, and rifampin. Vancomycin intermediate resistance in Staphylococcus aureus has been sparsely
reported in the literature, but, to the best of our knowledge, no
cases of vancomycin-resistant MRSA have occurred in hand
infections8. Despite frequent use, vancomycin still remains an
effective first-line agent for the empiric treatment for hand
infections.
The present study had several limitations. The retrospective
design limited the patients whom we were able to identify. Additionally, our local prevalence of MRSA may be dissimilar to
non-urban medical centers, and our results may not be generalized to other regions. Further, the number of polymicrobial infections may have been overestimated, as some culture specimens
were obtained in a non-sterile environment. We were not able to
accurately retrieve the number of culture specimens obtained by
bedside procedures; however, we routinely attempt to reduce
contamination during bedside procedures with sterile draping
and chlorhexidine-alcohol skin preparation prior to incision.
Infections caused by MRSA have a substantial presence,
especially in urban areas21. In our region, MRSA was found in
nearly half of all hand infections, and those isolates became
increasingly resistant to clindamycin and levofloxacin over the
study period. As a result, we would not recommend these drugs
as empiric antibiotics to clinicians who practice in endemic areas
with a significant prevalence of MRSA. The Centers for Disease
Control and Prevention do not recommend antibiotics for
empiric therapy that have a regional resistance that exceeds 10%
(Fig. 2)22. However, other therapeutics such as vancomycin,
tetracycline, moxifloxacin, and trimethoprim-sulfamethoxazole

still appear to have potent activity against MRSA. Organisms that
grew on culture from specimens from polymicrobial infections
were often sensitive to most antibiotics, and we would not recommend empiric treatment for anaerobic or gram-negative
bacteria unless specific situations such as bite wounds, aquatic
injuries, or severe infections warranted such coverage. In this
series, infections caused by bite wounds were generally susceptible to beta-lactam antibiotics, which may be selected in an
empiric management protocol under these circumstances. Finally, we would encourage future studies evaluating the efficacy
of common empiric antibiotics in other soft-tissue and joint
infections of the extremities with interval monitoring to ensure
relevant and current management recommendations. n
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